Cite
Real-life Experience With Rituximab-CHOP Every 21 or 14 Days in Primary Mediastinal Large B-cell Lymphoma.
MLA
Karakatsanis, Stamatis J., et al. “Real-Life Experience With Rituximab-CHOP Every 21 or 14 Days in Primary Mediastinal Large B-Cell Lymphoma.” In Vivo (Athens, Greece), vol. 36, no. 3, May 2022, pp. 1302–15. EBSCOhost, https://doi.org/10.21873/invivo.12831.
APA
Karakatsanis, S. J., Bouzani, M., Symeonidis, A., Angelopoulou, M. K., Papageorgiou, S. G., Michail, M., Gainaru, G., Kourti, G., Sachanas, S., Kalpadakis, C., Katodritou, E., Leonidopoulou, T., Kotsianidis, I., Hatzimichael, E., Kotsopoulou, M., Dimou, M., Variamis, E., Boutsis, D., Kanellias, N., … Vassilakopoulos, T. P. (2022). Real-life Experience With Rituximab-CHOP Every 21 or 14 Days in Primary Mediastinal Large B-cell Lymphoma. In Vivo (Athens, Greece), 36(3), 1302–1315. https://doi.org/10.21873/invivo.12831
Chicago
Karakatsanis, Stamatis J, Maria Bouzani, Argyris Symeonidis, Maria K Angelopoulou, Sotirios G Papageorgiou, Michail Michail, Gabriella Gainaru, et al. 2022. “Real-Life Experience With Rituximab-CHOP Every 21 or 14 Days in Primary Mediastinal Large B-Cell Lymphoma.” In Vivo (Athens, Greece) 36 (3): 1302–15. doi:10.21873/invivo.12831.